Screener
Aktis Oncology, Inc. AKTS Q2 2026 earnings
Reported August 13, 2026 · After market close
Revenue$3.4MBeat by $686.3K
EPS-$0.44Miss by $0.01
Revenue estimate$2.7M
EPS estimate-$0.43
Next report
Date not yet announcedVersus estimates
Revenue
Q3 2026$3.9MMiss by $968.5K
Q2 2026$3.4MBeat by $686.3K
Q1 2026$3.2MBeat by $997.0KQ4 2024$1.7MMiss by $1.6MQ4 2025$4.6MDiluted EPS
Q3 2026-$0.54Miss by $0.07
Q2 2026-$0.44Miss by $0.01
Q1 2026-$0.38Miss by $0.07Q4 2024-$1.27Beat by $20.32Q4 2025-$60.17FAQ
- When did Aktis Oncology, Inc. report Q2 2026 earnings?
- Aktis Oncology, Inc. (AKTS) reported Q2 2026 earnings on August 13, 2026 after market close.
- What were Aktis Oncology, Inc.'s Q2 2026 revenue and EPS?
- Aktis Oncology, Inc. reported revenue of $3.4M and eps of $-0.44 for Q2 2026.
- Did Aktis Oncology, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $2.7M by $686.3K. EPS missed the consensus estimate of $-0.43 by $0.01.
- Where can I find Aktis Oncology, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-349133) and the 10-Q periodic report (0001193125-26-349144) directly on SEC EDGAR. The filing index links above go to sec.gov.
